TSRL, INC.

Address

540 AVIS DR STE A
ANN ARBOR, MI, 48108-7906

Information

DUNS: 156551699
# of Employees: 5

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Microneedle Delivery of Zanamivir for Treatment of Influenza Infections

    Amount: $300,000.00

    Abstract Yearly influenza epidemics strike millions of people causing up to deaths Fatality caused by most seasonal influenza viruses is andlt but with significant mortality in the yo ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Broad Spectrum Antiviral Nucleoside Phosphonate Analogs

    Amount: $2,987,766.00

    DESCRIPTION provided by applicant The Working Group for Civilian Biodefense reviewed potential biological threat agents and listed those considered to pose the greatest threat to the civilian popul ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  3. Nucleoside Phosphonate Analogs for the Treatment of Adenoviral Infection

    Amount: $599,360.00

    DESCRIPTION provided by applicant Adenovirus can be a significant health risk for immune compromised patients both adult and pediatric patients In pediatric patients in particular complications ...

    SBIRPhase I2014Department of Health and Human Services
  4. Broad Spectrum Antiviral Nucleoside Phosphonate Analogs

    Amount: $597,046.00

    DESCRIPTION: The Working Group for Civilian Biodefense has identified orthopox DNA viruses such as variola as a potential bioterrorism threat, and numerous other DNA viruses, including herpes, adeno, ...

    SBIRPhase I2013Department of Health and Human Services
  5. Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability

    Amount: $2,585,246.00

    DESCRIPTION (provided by applicant): Virally-encoded neuraminidase plays a key role in the life-cycle of the influenza virus. A class of anti-influenza drugs that inhibits the action of neuraminidase ...

    SBIRPhase II2011Department of Health and Human Services
  6. Novel prodrugs for treatment of human CMV infection

    Amount: $591,457.00

    DESCRIPTION (provided by applicant): As a result of the widespread use of antiviral prophylaxis and pre-emptive therapy, the incidence and severity of human cytomegalovirus (HCMV) disease and its indi ...

    SBIRPhase I2010Department of Health and Human Services
  7. Development of the orally delivered, non-absorbable ACE inhibitor enalaprilat for

    Amount: $197,747.00

    DESCRIPTION (provided by applicant): A major limitation with most current medical therapies for inflammatory bowel disease (IBD) is the indiscriminant immunosuppressive effect of these drugs. We have ...

    SBIRPhase I2010Department of Health and Human Services
  8. Development of orally delivered, non-absorbable AT1 receptor antagonists for infl

    Amount: $268,620.00

    DESCRIPTION (provided by applicant): A major limitation with most current medical therapies for inflammatory bowel disease (IBD) is the indiscriminant immunosuppressive effect of these drugs. We have ...

    SBIRPhase I2009Department of Health and Human Services
  9. Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability

    Amount: $185,621.00

    DESCRIPTION (provided by applicant): Virally-encoded neuraminidase plays a key role in the life-cycle of the influenza virus. A class of anti-influenza drugs that inhibits the action of neuraminidase ...

    SBIRPhase I2009Department of Health and Human Services
  10. Bile acid conjugates for improving the oral bioavailability of bisphosphonates

    Amount: $255,852.00

    DESCRIPTION (provided by applicant): Bisphosphonates are chemically and enzymatically stable analogues of inorganic pyrophosphate that interfere with specific biochemical and enzymatic pathways of the ...

    SBIRPhase I2008Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government